Search IconSearch
July 22, 2019/Cancer

Endometrial Cancer Outcomes in Women Under 40

Characterizing endometrial cancer in young patients diagnosed before age 40

Illustration of endometrial cancer

by Ji Son, MD, MS, Mariam AlHilli, MD


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The prevalence of endometrial cancer in women 40 years and younger has been previously estimated at approximately 5%. Due to the rarity of this diagnosis in young women, few studies exist examining the clinical characteristics of young women with endometrial cancer. At the Society for Gynecologic Oncology’s 50th Annual Meeting on Women’s Cancer, held in Honolulu from March 16-19, 2019, we presented data characterizing endometrial cancer in patients diagnosed before age 40 who received cancer care at Cleveland Clinic.

Significant differences in progression free survival

The diagnosis of endometrial cancer in young women can be difficult to make, compared to older and postmenopausal women who present with postmenopausal bleeding. Age is an important prognostic factor in endometrial cancer, as increased age is associated with worse survival and a higher risk of recurrence. Research is limited regarding survival in endometrial cancer in younger women. In addition, many young women with endometrial cancer may desire fertility-preservation, in which they choose to undergo non-surgical treatment with anti-estrogen medication or intrauterine device to maintain their ability to get pregnant in the future. The impact of this strategy on endometrial cancer outcomes is unknown. To our knowledge, this is one of the largest groups of patients under age 40 with endometrial cancer studied in the literature to date.

We found that young women with endometrial cancer are more likely to be obese and harbor a concurrent ovarian cancer. The rate of concurrent ovarian cancer in our population was approximately 9%. Having a diagnosis of ovarian cancer at the same time as endometrial cancer does not seem to affect a patient’s prognosis since both cancers are typically diagnosed at an early stage. One in five women in our cohort of patients chose to preserve fertility. However, this strategy was successful in less than 25% of these patients.

Our data confirm previous findings that younger women with endometrial cancer have more favorable prognostic factors compared to older patients. In our analysis, we found that women under 40 with endometrial cancer are more likely to recur than patients with endometrial cancer in the 41-60 age group after adjusting for known adverse prognostic factors. Although this may be due to failure of medical therapy, this treatment strategy does not adversely affect overall survival as most of these patients eventually undergo definitive surgical treatment. The success of this treatment strategy requires close surveillance by a gynecologic oncologist and the involvement of a multidisciplinary care team.


Mismatch repair protein deficiency could be prognostic tool

Women in our study underwent screening for Lynch syndrome through a pathology-based test. Based on this, women were classified to have intact mismatch repair protein expression or deficiency (also known as microsatellite instability). Women with Lynch syndrome are often diagnosed with endometrial cancer at a younger age. However, we found that the incidence of Lynch syndrome and mismatch repair deficiency was not influenced by age, and that mismatch repair deficiency predicted a worse prognosis when caused by methylation of the gene MLH1. There is ongoing research on the use of mismatch repair protein deficiency as a prognostic marker in endometrial cancer, which will be critical in the contemporary management of endometrial cancer.


Related Articles

Reviewing dental scans
July 8, 2024/Cancer
A Call for More Interdisciplinary and Preventive Care in New Osteoradionecrosis Guidelines

New guidelines offer insight into emerging therapies, dental issues and more

Dr. AlHilli
July 3, 2024/Cancer/Patient Support
Prehabilitation Program Aims to Improve Outcomes for Older Patients with Ovarian or Pancreatic Cancer

Clinical trial to assess the value of nutritional, physical therapy and social supports prior to preoperative chemotherapy

Dr. Nahleh
June 26, 2024/Cancer/Patient Support
Systemic Treatment a Major Factor Impacting Survival of Patients with Breast Cancer with Brain Metastasis

Research demonstrates improved overall survival for patients receiving comprehensive treatment for breast cancer in addition to radiation or surgical intervention for brain cancer

Image showing Dr. Gupta
June 20, 2024/Cancer/Research
Trailblazing Urothelial Cancer Treatments (Podcast)

Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’

Dr. Grobmyer and team
June 14, 2024/Cancer/Innovations
Fatima bint Mubarak Center Addresses Inequities in Cancer Care

Cleveland Clinic Cancer Institute brings multidisciplinary care, precision oncology and clinical research to the United Arab Emirates

Lung cancer cells
June 5, 2024/Cancer/Research
Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib

Extent of baseline burden impacts progression-free and overall survival

cancer cells
June 4, 2024/Cancer/Research
Researchers Identify Tumor Microbiome Differences in Early- vs. Average-Onset Pancreatic Adenocarcinoma

Further study warranted to better understand the clinical implications of these findings

car T-cells
June 3, 2024/Cancer/Research
CAR T-Cell Treatment Offers Hope for Richter Transformation

Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel